Acarbose

DRUG INFORMATION

  ADULT
    - Dosage of acarbose tablets must be individualized on the basis of both
      effectiveness and tolerance while not exceeding the maximum recommended dose of
      100 mg t.i.d.
      Source: US FDA label for acarbose (Acarbose), section 'dosage and administration',
      retrieved 2026-08-29
    - Initial Dosage The recommended starting dosage of acarbose tablets is 25 mg given
      orally three times daily at the start (with the first bite) of each main meal.
      Source: US FDA label for acarbose (Acarbose), section 'dosage and administration',
      retrieved 2026-08-29
    - This may be achieved by initiating treatment at 25 mg once per day and
      subsequently increasing the frequency of administration to achieve 25 mg t.i.d.
      Source: US FDA label for acarbose (Acarbose), section 'dosage and administration',
      retrieved 2026-08-29

  CHILD
    - Safety and effectiveness of acarbose tablets in pediatric patients have not been
      established.
      Source: US FDA label for acarbose (Acarbose), section 'pediatric use', retrieved
      2026-08-29

  RENAL IMPAIRMENT
    - No kidney-impairment dose in this label. Not a statement that none is needed.
      Source: Read and found silent: the US FDA label for acarbose (Acarbose), retrieved
      2026-08-29

  HEPATIC IMPAIRMENT
    - No liver-impairment dose in this label. Not a statement that none is needed.
      Source: Read and found silent: the US FDA label for acarbose (Acarbose), retrieved
      2026-08-29

  PREGNANCY
    - Teratogenic Effects: Pregnancy Category B.
      Source: US FDA label for acarbose (Acarbose), section 'pregnancy', retrieved
      2026-08-29
    - The safety of acarbose tablets in pregnant women has not been established.
      Source: US FDA label for acarbose (Acarbose), section 'pregnancy', retrieved
      2026-08-29
    - Reproduction studies have been performed in rats at doses up to 480 mg/kg
      (corresponding to 9 times the exposure in humans, based on drug blood levels) and
      have revealed no evidence of impaired fertility or harm to the fetus due to
      acarbose.
      Source: US FDA label for acarbose (Acarbose), section 'pregnancy', retrieved
      2026-08-29

  BREASTFEEDING
    - A small amount of radioactivity has been found in the milk of lactating rats after
      administration of radiolabeled acarbose.
      Source: US FDA label for acarbose (Acarbose), section 'nursing mothers', retrieved
      2026-08-29
    - It is not known whether this drug is excreted in human milk.
      Source: US FDA label for acarbose (Acarbose), section 'nursing mothers', retrieved
      2026-08-29
    - Because many drugs are excreted in human milk, acarbose tablets should not be
      administered to a nursing woman.
      Source: US FDA label for acarbose (Acarbose), section 'nursing mothers', retrieved
      2026-08-29